Such forward-looking statements include, but are not limited to, statements about the benefits of the proposed transaction, including anticipated future financial and operating results, T-Mobile’s and ...

(SK Biopharm), a biopharmaceutical arm of SK Group, will establish a joint venture ... epilepsy treatment is expected to grow to US$1.8 billion by 2032, with North America accounting for some ...